& Sharfi, A
Disclosures: Tae-Hwi Schwantes-An: Target RWE: Consultant, Eduardo Vilar-Gomez: Nothing to Disclose, Marco Abreu: Nothing to Disclose, Brent Neuschwander-Tetri: Akero: Consultant, Aligos: Consultant, Arrowhead: Consultant, Corcept: Consultant, GSK: Consultant, Hepion: Consultant, HIstoIndex: Consultant, Madrigal: Consultant, Madrigal: Grant/Research Support, Merck: Consultant, Mirum: Consultant, Sagimet: Consultant, Senseion: Consultant, HepGene: Stock privately held company, HeptaBio: Stock privately held company, Miriam Vos: Nothing to Disclose, Jian Wang: Nothing to Disclose, Xiuqing Guo: Nothing to Disclose, Jingyi Tan: Nothing to Disclose, Robert A Hegele: Nothing to Disclose, Nicholas Davidson: Nothing to Disclose, George Hindy: Regeneron Pharmaceuticals: Employee, Luca Lotta: Nothing to Disclose, Niek Verweij: Nothing to Disclose, Jerome Rotter: Nothing to Disclose, Naga Chalasani: Madrigal: Consultant, Zydus, Ipsen, Pfizer, Merck, Altimmune, GSK: Consultant, Exact Sciences: Grant/Research Support, NIH: Grant/Research Support 2567 EXPLORING THE PROTECTIVE ROLE OF LYPLAL1 LOSS-OF-FUNCTION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Rawdat Hussain 1 Chinmay Raut 1 Prabhu Ponnandy 1 Akram Irshaid 1 Brian Halligan 2 Elizabeth Speliotes 2 , 1 University of Michigan, 2 University of Michigan Medical Center Background: Human genetics studies have linked single-nucleotide polymorphisms near LYPLAL1 with metabolic dysfunction-associated steatotic liver disease (MASLD)
Practicing with a syringe technique guide until the process feels automatic removes much of the stress
Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors
Aunque estos estudios estn publicados en revistas indexadas, la replicacin independiente por parte de otros grupos de investigacin sigue siendo insuficiente para extraer conclusiones definitivas sobre la eficacia teraputica en humanos
